Telos Rx Tirzepatide Review: Cost, Formats & Honest Verdict (2026)

Telos Rx is a LegitScript-certified, HIPAA-compliant compounded telehealth with an unusually broad tirzepatide menu — injectable, oral, and microdosed — and a low annual entry price. This review covers what Telos Rx is, what it dispenses, the compounded-versus-brand distinction, its real pricing, and the catches. We disclose an affiliate relationship with Telos Rx; it never changes our scoring, and every fact here comes from Telos Rx's own program.

What Telos Rx is

Telos Rx is a LegitScript-certified, HIPAA-compliant compounded telehealth. Its tirzepatide menu is unusually broad: compounded injectable, oral, and microdosed tirzepatide, plus compounded semaglutide. U.S. providers and licensed pharmacies review an online intake; published GLP-1 pricing starts at $49/month for microdosed tirzepatide on a 12-month plan and $99/month for tirzepatide on an annual plan, with shorter first-month plans at $145/$199/$399. HSA/FSA is accepted with free 48-hour shipping. The broader catalog also spans semaglutide, PT-141, intranasal NAD+, recovery peptides, and HRT, though pricing outside the GLP-1 menu is not published and the states served are not listed.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Every Telos Rx formulation is compounded — injectable, oral, and microdosed alike — none is the FDA-approved branded product. That distinction matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. The oral tirzepatide route in particular lacks the injectable's robust absorption and efficacy evidence.

What Telos Rx costs in 2026

Telos Rx advertises low annual-plan entry pricing: from $99/month for tirzepatide on an annual plan and from $49/month for microdosed tirzepatide on a 12-month plan, with HSA/FSA accepted and free 48-hour shipping. The catch is the commitment: the lowest headline prices require a 6- to 12-month plan, while shorter first-month plans run $145/$199/$399. So the sub-$100 figure is a long-commitment rate, not a month-to-month price.

For context, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply). Telos Rx's compounded annual pricing undercuts that, but you are comparing a non-FDA-approved product to the approved one, and committing for the year. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Telos Rx's strengths are its multiple tirzepatide formats (injectable, oral, and microdosed — a rare combination), LegitScript certification and HIPAA compliance with U.S. providers and licensed pharmacies, a low published entry price on annual plans with HSA/FSA and free 48-hour shipping, and a broad adjacent catalog. The trade-offs: every formulation is compounded (not the FDA-approved brand); the lowest prices require a 6- to 12-month commitment (short plans run $145/$199/$399 for the first month); pricing is opaque outside the GLP-1 menu and the states served are not published; and there are no named clinicians and thin third-party reviews. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand injectable molecule; compounded versions — and especially oral and microdosed formats — were never tested in those trials, so the trial efficacy cannot be assumed to transfer. The full picture is in our tirzepatide evidence guide and our look at oral tirzepatide.

The honest verdict

Telos Rx is a good fit if you want multiple tirzepatide formats from a LegitScript-certified provider at a low annual price, and you are comfortable with a compounded, non-FDA-approved product and a 6- to 12-month commitment. The LegitScript certification is a genuine trust signal most compounded startups lack. The reservations are the long-commitment pricing, the opaque non-GLP-1 pricing and unpublished states served, no named clinicians, and — for the oral and microdosed routes — a thinner evidence base. If you prefer a flat monthly price with included support and no annual lock-in, weigh CoreAge Rx; if you specifically want brand tirzepatide, price it against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.